TransCanna Holdings (TCNAF) Fair Value & Analysis
Healthcare · US · Market cap $12.0K
TransCanna Holdings
TCNAF · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0900 to $0.0001 (−99.9%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0001 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
TransCanna Holdings (TCNAF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $3.9M. Revenue declined 29.8% year over year. Net debt stands at $18.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
TransCanna Holdings Inc., through its subsidiaries, engages in the manufacturing, transportation, and distribution of cannabis related products in the United States. It provides cannabis for licensed operators involved in the cultivation, processing, distribution, and crop management in California. The company was incorporated in 2017 and is headquartered in West Vancouver, Canada.
Revenue & earnings trend
FY2017 – FY2021 · reported fiscal years
TransCanna Holdings reported revenue of $4.0M in FY2021 versus $0 in FY2018. Reported net income was −$13.1M in FY2021.
Is TCNAF fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TransCanna Holdings (TCNAF) undervalued?
What is the fair value of TCNAF?
What is the quality score of TCNAF?
What is the revenue of TransCanna Holdings (TCNAF)?
What is the net profit margin of TCNAF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.